VLA 0.00% $1.75 viralytics limited

Ann: Viralytics to Present New CAVATAK Clinical Data at AACR, page-9

  1. 11,705 Posts.
    lightbulb Created with Sketch. 1690
    wow, yes what a difference a day makes.

    For the last few years the vla sp plods along or down and then out comes some trial results snippets and it goes up to a new level.

    Given two podium slots have been given and vla's constantly good trial result snippets I think we will hit a new high even before the news comes out.

    Of course it is not just that good results matter to us, but also to those looking to partner or do a take over. Maybe these results might just be the push needed for that to happen.

    ok, I shouldn't get too carried away yet, but it is nice to feel positivity after this years sp decline.

    Cheers
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.